The ISCHEMIA Trial: And the Winner Is… the Patient. by Avanzas, P & Kaski, JC
© RADCLIFFE CARDIOLOGY 2021
Access at: www.ECRjournal.com
ISCHEMIA Trial
Mainly influenced by the results of the most recent large comparative 
studies of medical versus revascularisation treatment, the current 
European Society of Cardiology guidelines for the management of 
patients with chronic coronary syndrome (CCS) recommend optimal 
medical treatment (OMT) as a key therapy for reducing symptoms, 
halting the progression of atherosclerosis and preventing 
atherothrombotic events. Myocardial revascularisation is also strongly 
recommended, in addition to medical treatment, in the management of 
a specific CCS.1
The CCS therapeutic scenario has evolved markedly over the past few 
years. Earlier trials suggested myocardial revascularisation to both 
alleviate symptoms and improve prognosis in patients with stable angina, 
but contemporary studies report similar rates of death and MI in stable 
angina patients receiving OMT only when compared with percutaneous 
coronary intervention (PCI) as in the COURAGE trial, or PCI or coronary 
artery bypass grafting, as in the BARI 2D trial.2–5 These two studies 
received criticism regarding potential limitations in the study design (i.e. 
selection bias), given that randomisation was performed after the 
coronary anatomy was known; there was a lack of a defined threshold for 
myocardial ischemia for inclusion; and drug-eluting stents were used in 
only a very small number of patients. 
The International Study of Comparative Health Effectiveness with Medical 
and Invasive Approaches (ISCHEMIA) trial, the latest of the larger 
contemporary studies comparing OMT with coronary revascularisation for 
the management of stable angina, attempted to overcome at least some 
of these limitations. The ISCHEMIA trial aimed to determine the best 
management strategy for higher risk patients with stable ischaemic heart 
disease and moderate or severe ischaemia. Eligible patients were 
randomly assigned, in a 1:1 ratio, to an initial invasive strategy of OMT, 
angiography, and revascularisation when feasible, or to an initial 
conservative strategy of OMT alone, with angiography reserved for failure 
of medical therapy. The primary outcome was a composite of death from 
cardiovascular causes, MI, hospitalisation for unstable angina or heart 
failure or resuscitated cardiac arrest. A key secondary outcome was death 
from cardiovascular causes or MI. 
The results were presented in two main papers in the New England 
Journal of Medicine.6,7 In brief, over a median of 3.2 years, 318 primary 
outcome events occurred in the invasive strategy group and 352 occurred 
in the conservative strategy group. At 6 months, the cumulative event rate 
was 5.3% in the invasive strategy group and 3.4% in the conservative 
strategy group (difference 1.9%; 95% CI [0.8–3.0]); at 5  years, the 
cumulative event rate was 16.4% and 18.2%, respectively (difference, 
−1.8%; 95% CI [−4.7, 1.0]). Results were similar with respect to the key 
secondary outcome. The incidence of the primary outcome was sensitive 
to the definition of MI, and a secondary analysis yielded more procedural 
MIs of uncertain clinical importance. There were 145 deaths in the invasive 
strategy group and 144 deaths in the conservative strategy group (HR 1.05; 
95% CI [0.83–1.32]).
Undeniably, ISCHEMIA addressed a very important issue, namely the 
comparative effects of coronary revascularisation and OMT management 
in a contemporary cohort of patients with stable coronary disease, 
currently described as CCS, receiving the most up-to-date medical 
treatment, including therapies shown to beneficially modify the natural 
history of ischaemic heart disease.
The inclusion criteria were rigorous: for patients to be included in the 
study, coronary artery disease was defined as a >50% diameter reduction 
on non-invasive CT coronary angiography, and myocardial ischemia was 
required to be documented (with 50% of randomised patients undergoing 
nuclear medicine assessment). 
The original primary endpoint of ISCHEMIA was cardiovascular death or 
MI. Of importance, and representing at least a minor limitation of the 
study, in view of the low rate of events and slow patient recruitment, the 
independent advisory panel of the National Heart, Lung, and Blood 
Institute modified the double primary endpoint of the trial to incorporate a 
combination of five variables, that is, cardiovascular death, MI, resuscitated 
cardiac arrest, and hospitalisation for unstable angina or heart failure.8 
Although understandable, given the unexpected difficulties regarding 
recruitment, this amendment of the study protocol is generally considered 
to represent an undesirable event in clinical studies of this sort.9
Although the ISCHEMIA trial provides extremely useful information 
regarding the initial management of patients with CCS, the study is not 
strictly a PCI versus OMT trial, given that after follow-up, only 80% of 
patients in the invasive strategy group did indeed undergo 
revascularisation, and 23% of the subjects assigned to the conservative 
strategy group received revascularisation. Moreover, 74% of the patients 
underwent revascularisation with PCI, while coronary artery bypass 
grafting was performed in the remaining cases.
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What exactly did ISCHEMIA report regarding the relative roles of invasive 
or interventional strategies and OMT versus OMT alone? The main results 
of the study indicate that when the two treatment options were compared, 
there were no significant differences in the risk of the combined endpoint 
of cardiovascular death, MI, resuscitated cardiac arrest, and hospitalisation 
for unstable angina or heart failure, between the two options.
ISCHEMIA showed that an initial conservative strategy entails a lower risk 
of developing a periprocedural MI, for obvious reasons, or hospitalisation 
for heart failure, while an initial invasive strategy carries a lower risk of MI 
and hospitalisation for unstable angina, and results in greater symptomatic 
benefit and improvement of quality of life in those patients with frequent 
angina symptoms. In relation to adverse events recorded in the study, 
intervention specialists often argue that it might be reasonable to assume 
that periprocedural MIs do not have the same prognostic implications as 
larger spontaneous MIs. Moreover, the curves of spontaneous MI and of 
the primary endpoint continued to diverge at the end of the follow-up, 
favouring the revascularisation strategy over time, despite the relatively 
large proportion of patients in the conservative group who underwent 
revascularisation. Therefore, further analysis of the implications of these 
findings in stable angina patients is necessary, and constructive 
conversations between the interventionists and clinical cardiologists 
managing these patients need to take place sooner rather than later.
In summary, the ISCHEMIA trial is an extremely important study that has 
undoubtedly highlighted the importance of ‘aggressive’ OMT in patients 
with stable coronary disease, and shown that the managing clinician can 
afford to start OMT in patients with stable angina despite the presence of 
significant coronary artery stenosis (except for left main coronary artery 
disease and severe angina) without the need to rush patients to coronary 
revascularisation. ISCHEMIA, however, is not about the victory of OMT 
versus myocardial revascularisation, or vice versa, but about selecting the 
right intervention for the right patient and providing stable angina patients 
with all the relevant information regarding the true beneficial effects and 
problems associated with both treatment options. They should not expect 
revascularisation to improve survival and prevent heart attacks, and they 
should be made aware of the disease-modifying potential of OMT, 
particularly given the incorporation of the most recent pharmacological 
lipid-lowering agents, anti-diabetes drugs and non-anti-vitamin K 
anticoagulants into the current therapeutic armamentarium. 
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